pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2022-32-2-232-238pulmo-3855Research ArticleОБЗОРЫREVIEWКашель при новой коронавирусной инфекции (COVID-19): рациональные подходы к фармакотерапииCough associated with the new coronavirus infection (COVID-19): rational approaches to pharmacotherapyhttps://orcid.org/0000-0003-4294-5531ОковитыйС. В.OkovityiS. V.

Оковитый Сергей Владимирович – доктор медицинских наук, профессор, заведующий кафедрой фармакологии и клинической фармакологии 

197376, Россия, Санкт-Петербург, ул. Проф. Попова, 14а

Sergey V. Okovityi, Doctor of Medicine, Professor, Head of the Department of Pharmacology and Clinical Pharmacology

ul. Prof. Popova 14а, Saint-Petersburg, 197022, Russia

sergey.okovity@pharminnotech.comhttps://orcid.org/0000-0003-3681-0067СухановД. С.SukhanovD. S.

Суханов Дмитрий Сергеевич – доктор медицинских наук, врач-пульмонолог 

190103, Россия, Санкт-Петербург, наб. реки Фонтанки, 152а

Dmitry S. Sukhanov, Doctor of Medicine, pulmonologist

nab. reki Fontanki 152а, Saint-Petersburg, 190103, Russia

dmitriysukhanovl@mail.ruhttps://orcid.org/0000-0002-0934-7313ЗайцевA. А.ZaicevA. A.

Зайцев Андрей Алексеевич – доктор медицинских наук, профессор, главный пульмонолог

SPIN: 6549-5154; Author ID: 217005

105094, Россия, Москва, Госпитальная пл., 3

Andrey A. Zaicev, Doctor of Medicine, Professor, Chief Pulmonologist

SPIN: 6549-5154; Author ID: 217005

Gospital’naya pl. 3, Moscow, 105229, Russia

 

a-zaicev@yandex.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный химико-фармацевтический университет» Министерства здравоохранения Российской ФедерацииРоссияSaint-Petersburg State Chemical and Pharmaceutical University, Healthcare Ministry of the Russian FederationRussian FederationСанкт-Петербургское государственное бюджетное учреждение здравоохранения «Противотуберкулезный диспансер № 12»РоссияSaint-Petersburg State Budgetary Healthcare Institution “Tuberculosis Dispensary No.12”Russian FederationФедеральное государственное бюджетное учреждение «Главный военный клинический госпиталь имени академика Н.Н.Бурденко» Министерства обороны Российской ФедерацииРоссияMain Military Clinical Hospital named after academician N.N.Burdenko, Ministry of Defense of the Russian FederationRussian Federation202202052022322232238Copyright © Оковитый С.В., Суханов Д.С., Зайцев A.А., 20222022Оковитый С.В., Суханов Д.С., Зайцев A.А.Okovityi S.V., Sukhanov D.S., Zaicev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/3855

Кашель, при котором снижается качество жизни и развиваются жизнеугрожающие состояния, является одним из самых частых симптомов новой коронавирусной инфекции (НКИ) (COVID-19).

Целью обзора явился анализ современных подходов к фармакотерапии кашля при НКИ с позиций патогенетического обоснования применения лекарственных препаратов. Рассмотрены представленные в литературе основные механизмы развития кашля при COVID-19, который связан с повреждением эпителия вирусом и последующим выделением биологически активных веществ, раздражающих афферентные окончания блуждающего нерва. Рассмотрены подходы к менеджменту кашля при COVID-19 с возможным применением противокашлевых (центрального и периферического действия) и мукоактивных препаратов (экспекторального, мукокинетического, муколитического, мукорегуляторного действия).

Заключение. По результатам анализа данных литературных источников и известных механизмов патогенеза кашля установлено, что приоритетная роль в терапии кашля при COVID-19 отводится именно противокашлевым препаратам.

Cough is one of the most frequent symptoms of the new coronavirus infection (COVID-19). It reduces the quality of life and contributes to the development of life-threatening conditions.

Aim

Aim. This article analyzes modern approaches to the pharmacotherapy of cough in patients with the new coronavirus infection from the standpoint of pathogenetic justification of the use of drugs. The main mechanisms of cough development in COVID-19 presented in the literature are considered. The cough is associated with virus-induced damage to the epithelium and subsequent release of biologically active substances that irritate the afferent endings of the vagus nerve. Approaches to cough management in COVID-19 with the possible use of antitussive (central and peripheral action) and mucoactive drugs (expectorants, mucokinetics, mucolytics, mucoregulators) are addressed.

Conclusion

Conclusion. Based on the literature data and pathogenesis, antitussive drugs play a crucial role in the treatment of cough in COVID-19.

COVID-19кашельмукоактивные препаратыпротивокашлевые препараты.COVID-19coughmucoactive drugsantitussive drugsReferencesЗайцев А.А., Чернов С.А., Крюков Е.В. и др. Практический опыт ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре (предварительные итоги и рекомендации). Лечащий врач. 2020; (6): 74–79. DOI: 10.26295/OS.2020.41.94.014.Zaytsev A.A., Chernov S.A., Kryukov E.V. et al. [Practical experience of managing patients with new coronavirus infection COVID-19 in hospital (preliminary results and guidelines)]. Lechashchiy Vrach. 2020; (6): 74–79. DOI: 10.26295/OS.2020.41.94.014 (in Russian).National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement [corporate author]. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020; 369: m1461. DOI: 10.1136/bmj.m1461.National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement [corporate author]. Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020; 369: m1461. DOI: 10.1136/bmj.m1461.Lovato A., Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020; 99 (9): 569–576. DOI: 10.1177/0145561320920762.Lovato A., Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020; 99 (9): 569–576. DOI: 10.1177/0145561320920762.Зайцев А.А., Оковитый С.В., Мирошниченко Н.А., Крюков Е.В. Кашель: Методические рекомендации для врачей. М.: ГВКГ им. Н.Н.Бурденко; 2021. Доступно на: https://www.researchgate.net/publication/354162540_Kasel_Metodiceskie_rekomendacii_dla_vracej_Cough_Guidelines_for_physiciansZaytsev A.A., Okovityy S.V., Miroshnichenko N.A., Kryukov E.V. [Cough: Guidelines for physicians]. Moscow: Burdenko General Clinical Hospital; 2021. Available at: https://www.researchgate.net/publication/354162540_Kasel_Metodiceskie_rekomendacii_dla_vracej_Cough_Guidelines_for_physicians (in Russian).Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond.). 2021; 53 (10): 737–754. DOI: 10.1080/23744235.2021.1924397.Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond.). 2021; 53 (10): 737–754. DOI: 10.1080/23744235.2021.1924397.Цинзерлинг В.А., Вашукова М.А., Васильева М.В. и др. Вопросы патоморфогенеза новой коронавирусной инфекции (COVID-19). Журнал инфектологии. 2020; 12 (2): 5–11. DOI: 10.22625/2072-6732-2020-12-2-5-11.Tsinzerling V.A., Vashukova M.A., Vasil’eva M.V. [Issues of pathology of a new coronavirus infection CoVID-19.]. Zhurnal infektologii. 2020; 12 (2): 5–11. DOI: 10.22625/2072-6732-2020-12-2-5-11 (in Russian).Zaccone E.J., Lieu T., Muroi Y. et al. Parainfluenza 3 – induced cough hypersensitivity in the guinea pig airways. PLoS One. 2016; 11 (5): e0155526. DOI: 10.1371/journal.pone.0155526.Zaccone E.J., Lieu T., Muroi Y. et al. Parainfluenza 3 – induced cough hypersensitivity in the guinea pig airways. PLoS One. 2016; 11 5): e0155526. DOI: 10.1371/journal.pone.0155526.Deng Z., Zhou W., Sun J. et al. IFN-γ enhances the cough reflex sensitivity via calcium influx in vagal sensory neurons. Am. J. Respir. Crit. Care Med. 2018; 198 (7): 868–879. DOI: 10.1164/rc-cm.201709-1813OC.Deng Z., Zhou W., Sun J. et al. IFN-γ enhances the cough refl x sensitivity via calcium infl in vagal sensory neurons. Am. J. Respir. Crit. Care Med. 2018; 198 (7): 868–879. DOI: 10.1164/rccm.201709-1813OC.Patil M.J., Ru F., Sun H. et al. Acute activation of bronchopulmonary vagal nociceptors by type I interferons. J. Physiol. 2020; 598 (23): 5541–5554. DOI: 10.1113/JP280276.Patil M.J., Ru F., Sun H. et al. Acute activation of bronchopulmonary vagal nociceptors by type I interferons. J. Physiol. 2020; 598 (23): 5541–5554. DOI: 10.1113/JP280276.Chung K.F., Pavord I.D. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008; 371 (9621): 1364–1374. DOI: 10.1016/S0140-6736(08)60595-4.Chung K.F., Pavord I.D. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008; 371 (9621): 1364–1374. DOI: 10.1016/S0140-6736(08)60595-4.Scialo F., Daniele A., Amato F. et al. ACE2: The major cell entry receptor for SARS-CoV-2. Lung. 2020; 198 (6): 867–877. DOI: 10.1007/s00408-020-00408-4.Scialo F., Daniele A., Amato F. et al. ACE2: The major cell entry receptor for SARS-CoV-2. Lung. 2020; 198 (6): 867–877. DOI: 10.1007/s00408-020-00408-4.Абатуров А.Е., Агафонова Е.А., Кривуша Е.Л., Никулина А.А. Патогенез COVID-19. Здоровье ребенка. 2020; 15 (2): 133–144. DOI: 10.22141/2224-0551.15.2.2020.200598.Abaturov A.E., Agafonova E.A., Krivusha E.L., Nikulina A.A. [Pathogenesis of COVID-19]. Zdorov’e rebenka. 2020; 15 (2): 133– 144. DOI: 10.22141/2224-0551.15.2.2020.200598 (in Russian).Dalan R., Bornstein S.R., El-Armouche A. et al. The ACE-2 in COVID-19: Foe or friend? Horm. Metab. Res. 2020; 52 (5): 257–263. DOI: 10.1055/a-1155-0501.Dalan R., Bornstein S.R., El-Armouche A. et al. The ACE-2 in COVID-19: Foe or friend? Horm. Metab. Res. 2020; 52 (5): 257–263. DOI: 10.1055/a-1155-0501.Colarusso C., Terlizzi M., Pinto A., Sorrentino R. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. Br. J. Pharmacol. 2020; 177 (21): 4866–4872. DOI: 10.1111/bph.15154.Colarusso C., Terlizzi M., Pinto A., Sorrentino R. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. Br. J. Pharmacol. 2020; 177 (21): 4866–4872. DOI: 10.1111/bph.15154.Hewitt M.M., Adams G.Jr., Mazzone S.B. et al. Pharmacology of bradykinin-evoked coughing in guinea pigs. J. Pharmacol. Exp. Ther. 2016; 357 (3): 620–628. DOI: 10.1124/jpet.115.230383.Hewitt M.M., Adams G.Jr., Mazzone S.B. et al. Pharmacology of bradykinin-evoked coughing in guinea pigs. J. Pharmacol. Exp. Ther. 2016; 357 (3): 620–628. DOI: 10.1124/jpet.115.230383.Garvin M.R., Alvarez C., Miller J.I. et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020; 9: e59177. DOI: 10.7554/eLife.59177.Garvin M.R., Alvarez C., Miller J.I. et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020; 9: e59177. DOI: 10.7554/eLife.59177.Roche J.A., Roche R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J. 2020; 34 (6): 7265–7269. DOI: 10.1096/fj.202000967.Roche J.A., Roche R. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J. 2020; 34 (6): 7265–7269. DOI: 10.1096/fj.202000967.van de Veerdonk F.L., Kouijzer I.J.E., de Nooijer A.H. et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw. Open. 2020; 3 (8): e2017708. DOI: 10.1001/jamanetworkopen.2020.17708.van de Veerdonk F.L., Kouijzer I.J.E., de Nooijer A.H. et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw. Open. 2020; 3 (8): e2017708. DOI: 10.1001/jamanetworkopen.2020.17708.van de Veerdonk F.L., Netea M.G., van Deuren M. et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020; 9: e57555. DOI: 10.7554/eLife.57555.van de Veerdonk F.L., Netea M.G., van Deuren M. et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020; 9: e57555. DOI: 10.7554/eLife.57555.Dicpinigaitis P.V., Canning B.J. Is there (will there be) a postCOVID-19 chronic cough? Lung. 2020; 198 (6): 863–865. DOI: 10.1007/s00408-020-00406-6.Dicpinigaitis P.V., Canning B.J. Is there (will there be) a postCOVID-19 chronic cough? Lung. 2020; 198 (6): 863–865. DOI: 10.1007/s00408-020-00406-6.Зайцев А.А. Кашель: проблемы и решения. Практическая пуль­ монология. 2020; (2): 78–86. Доступно на: https://atmosphere­ph.ru/modules/Magazines/articles//pulmo/pp_2_2020_78.pdfZaytsev A.A.. [Cough: problems and solutions]. Prakticheskaya pul’monologiya. 2020; (2): 78–86. Available at: https://atmosphere­ph.ru/modules/Magazines/articles//pulmo/pp_2_2020_78.pdf (in Russian).Undem B.J., Chuaychoo B., Lee M.G. et al. Subtypes of vagal afferent C-fi in guinea-pig lungs. J. Physiol. 2004; 556 (Pt 3): 905–917. DOI: 10.1113/jphysiol.2003.060079.Undem B.J., Chuaychoo B., Lee M.G. et al. Subtypes of vagal afferent C-fi in guinea-pig lungs. J. Physiol. 2004; 556 (Pt 3): 905–917. DOI: 10.1113/jphysiol.2003.060079.Chou Y.L., Scarupa M.D., Mori N., Canning B.J. Differential effects of airway afferent nerve subtypes on cough and respiration in anesthetized guinea pigs. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008; 295 (5): R1572–1584. DOI: 10.1152/ajpregu.90382.2008.Chou Y.L., Scarupa M.D., Mori N., Canning B.J. Differential effects of airway afferent nerve subtypes on cough and respiration in anesthetized guinea pigs. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008; 295 (5): R1572–1584. DOI: 10.1152/ajpregu.90382.2008.Chou Y.L., Mori N., Canning B.J. Opposing effects of bronchopulmonary C-fiber subtypes on cough in guinea pigs. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2018; 314 (3): R489–498. DOI: 10.1152/ajpregu.00313.2017.Chou Y.L., Mori N., Canning B.J. Opposing effects of bronchopulmonary C-fiber subtypes on cough in guinea pigs. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2018; 314 (3): R489–498. DOI: 10.1152/ajpregu.00313.2017.Tatar M., Sant’Ambrogio G., Sant’Ambrogio F.B. Laryngeal and tracheobronchial cough in anesthetized dogs. J. Appl. Physiol. (1985). 1994; 76 (6): 2672–2679. DOI: 10.1152/jappl.1994.76.6.2672.Tatar M., Sant’Ambrogio G., Sant’Ambrogio F.B. Laryngeal and tracheobronchial cough in anesthetized dogs. J. Appl. Physiol. (1985). 1994; 76 (6): 2672–2679. DOI: 10.1152/jappl.1994.76.6.2672.Tatar M., Webber S.E., Widdicombe J.G. Lung C-fi receptor activation and defensive reflexes in anaesthetized cats. J. Physiol. 1988; 402: 411–420. DOI: 10.1113/jphysiol.1988.sp017212.Tatar M., Webber S.E., Widdicombe J.G. Lung C-fi receptor activation and defensive reflexes in anaesthetized cats. J. Physiol. 1988; 402: 411–420. DOI: 10.1113/jphysiol.1988.sp017212.Stone R.A., Worsdell Y.M., Fuller R.W., Barnes P.J. Effects of 5-hydroxytryptamine and 5-hydroxytryptophan infusion on the human cough reflex. J. Appl. Physiol. (1985). 1993; 74 (1): 396–401. DOI: 10.1152/jappl.1993.74.1.396.Stone R.A., Worsdell Y.M., Fuller R.W., Barnes P.J. Effects of 5-hydroxytryptamine and 5-hydroxytryptophan infusion on the human cough reflex. J. Appl. Physiol. (1985). 1993; 74 (1): 396–401. DOI: 10.1152/jappl.1993.74.1.396.Оковитый С.В., Зайцев А.А., Анисимова Н.А. Фармакодинамические подходы к применению мукоактивных препаратов. Лечащий врач. 2020; (10): 6–10. DOI: 10.26295/OS.2020.62.62.001.Okovityy S.V., Zaytsev A.A., Anisimova N.A. [Pharmacodynamic approaches to the use of mucoactive drugs]. Lechashchiy vrach. 2020; (10): 6–10. DOI: 10.26295/OS.2020.62.62.001 (in Russian).Morice A., Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Respir. Res. 2016; 3 (1): e000137. DOI: 10.1136/bmjresp-2016-000137.Morice A., Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Respir. Res. 2016; 3 (1): e000137. DOI: 10.1136/bmjresp-2016-000137.Bem J.L., Peck R. Dextromethorphan: An overview of safety issues. Drug Saf. 1992; 7 (3): 190–199. DOI: 10.2165/00002018-199207030-00004.Bem J.L., Peck R. Dextromethorphan: An overview of safety issues. Drug Saf. 1992; 7 (3): 190–199. DOI: 10.2165/00002018-199207030-00004.Lauterbach E.C. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med. Hypotheses. 2012; 78 (6): 693–702. DOI: 10.1016/j.mehy.2012.02.012.Lauterbach E.C. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med. Hypotheses. 2012; 78 (6): 693–702. DOI: 10.1016/j.mehy.2012.02.012.Matthys H., Bleicher B., Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J. Int. Med. Res. 1983; 11 (2): 92–100. DOI: 10.1177/030006058301100206.Matthys H., Bleicher B., Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J. Int. Med. Res. 1983; 11 (2): 92–100. DOI: 10.1177/030006058301100206.Werling L.L., Lauterbach E.C., Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 2007; 13 (5): 272–293. DOI: 10.1097/NRL.0b013e3180f60bd8.Werling L.L., Lauterbach E.C., Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 2007; 13 (5): 272–293. DOI: 10.1097/NRL.0b013e3180f60bd8.Gordon D.E., Jang G.M., Bouhaddou M. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583 (7816): 459–468. DOI: 10.1038/s41586-020-2286-9.Gordon D.E., Jang G.M., Bouhaddou M. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583 (7816): 459–468. DOI: 10.1038/s41586-020-2286-9.CHPA statement regarding use of dextromethorphan and COVID-19. CHPA. May 6, 2020. Available at: https://www.chpa.org/news/2020/05/chpa-statement-regarding-use-dextromethorphan-and-covid-19 [Accessed: December 29, 2020].CHPA statement regarding use of dextromethorphan and COVID-19. CHPA. May 6, 2020. Available at: https://www.chpa.org/news/2020/05/chpa-statement-regarding-use-dextromethorphan-and-covid-19 [Accessed: December 29, 2020].Enkirch T., Sauber S., Anderson D.E. et al. Identification and in vivo efficacy assessment of approved orally bioavailable human host protein-targeting drugs with broad anti-influenza A activity. Front. Immunol. 2019; 10: 1097. DOI: 10.3389/fimmu.2019.01097.Enkirch T., Sauber S., Anderson D.E. et al. Identification and in vivo efficacy assessment of approved orally bioavailable human host protein-targeting drugs with broad anti-influenza A activity. Front. Immunol. 2019; 10: 1097. DOI: 10.3389/fimmu.2019.01097.Sarkar I., Sen A. In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be eff ive against novel coronavirus disease (COVID-19). J Biomol. Struct. Dyn. [Preprint. Posted: 2020, Nov. 23]. DOI: 10.1080/07391102.2020.1850528.Sarkar I., Sen A. In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be eff ive against novel coronavirus disease (COVID-19). J. Biomol. Struct. Dyn. [Preprint. Posted: 2020, Nov. 23]. DOI: 10.1080/07391102.2020.1850528.J. Klein M., Musacchio J.M. High affinity dextromethorphan binding sites in guinea pig brain: Effect of sigma ligands and other agents. J Pharmacol. Exp. Ther. 1989; 251 (1): 207–215. Available at: https://jpet.aspetjournals.org/content/251/1/207Klein M., Musacchio J.M. High affinity dextromethorphan binding sites in guinea pig brain: Effect of sigma ligands and other agents. J. Pharmacol. Exp. Ther. 1989; 251 (1): 207–215. Available at: https://jpet.aspetjournals.org/content/251/1/207Plusa T. [Butamirate citrate in control of cough in respiratory tract inflammation]]. Pol. Merkur. Lekarski. 2017; 43 (254): 69–74 (in Polish).Plusa T. [Butamirate citrate in control of cough in respiratory tract infl tion]. Pol. Merkur. Lekarski. 2017; 43 (254): 69–74 (in Polish).Faruqi S., Wright C., Thompson R., Morice A.H. A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers. Br. J. Clin. Pharmacol. 2014; 78 (6): 1272–1280. DOI: 10.1111/bcp.12458.Faruqi S., Wright C., Thompson R., Morice A.H. A randomized placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers. Br. J. Clin. Pharmacol. 2014; 78 (6): 1272–1280. DOI: 10.1111/bcp.12458.Геппе Н.А., Кондюрина Е.Г., Галустян А.Н. и др. Ренгалин – новый препарат для лечения кашля у детей: промежуточные итоги многоцентрового сравнительного рандомизированного клинического исследования. Антибиотики и химиотерапия. 2014; 59 (7-8): 16–24. Доступно на: https://www.antibiotics­chemotherapy.ru/jour/article/view/555/555Geppe N.A., Kondyurina E.G., Galustyan A.N. et al. [Rengalin, a novel drug for treatment of cough in children: Intermediate data on multicentre, comparative randomized clinical trial]. Antibiotiki i khimioterapiya. 2014; 59 (7–8): 16–24. Available at: https://www.antibiotics­chemotherapy.ru/jour/article/view/555/555 (in Russian).Цыганко Д.В., Бердникова Н.Г., Екатеринчев В.А. Клиникофармакологические подходы к оптимизации терапии у кашляющего пациента. Медицинский совет. 2021; (4): 112–119. DOI: 10.21518/2079-701X-2021-4-112-119.Tsyganko D.V., Berdnikova N.G., Ekaterinchev V.A. [Clinical and pharmacological approaches to optimizing therapy in a coughing patient]. Medicinskiy sovet. 2021; (4): 112–119. DOI: 10.21518/2079-701X-2021-4-112-119 (in Russian).Harsanyi K., Tardos L., Feher I., Nagy G. Pharmacologic, clinico-pharmacologic and clinical effects of Libexin. Boll. Chim. Farm. 1973; 112 (10): 691–699.Harsanyi K., Tardos L., Feher I., Nagy G. Pharmacologic, clinico-pharmacologic and clinical effects of Libexin. Boll. Chim. Farm. 1973; 112 (10): 691–699.Lavezzo A., Melillo G., Clavenna G., Omini C. Peripheral site of action of levodropropizine in experimentally-induced cough: role of sensory neuropeptides. Pulm. Pharmacol. 1992; 5 (2): 143–147. DOI: 10.1016/0952-0600(92)90033-d.Lavezzo A., Melillo G., Clavenna G., Omini C. Peripheral site of action of levodropropizine in experimentally-induced cough: role of sensory neuropeptides. Pulm. Pharmacol. 1992; 5 (2): 143–147. DOI: 10.1016/0952-0600(92)90033-d.Shams H., Daffonchio L., Scheid P. Effects of levodropropizine on vagal afferent C-fibres in the cat. Br. J. Pharmacol. 1996; 117 (5): 853–858. DOI: 10.1111/j.1476-5381.1996.tb15271.x.Shams H., Daffonchio L., Scheid P. Effects of levodropropizine on vagal afferent C-fibres in the cat. Br. J. Pharmacol. 1996; 117 (5): 853–858. DOI: 10.1111/j.1476-5381.1996.tb15271.x.Gunella G., Zanasi A., Massimo Vanasia C.B. [Efficacy and safety of the use of levodropropizine in patients with chronic interstitial lung diseases]. Clin. Ter. 1991; 136 (4): 261–266 (in Italian).Gunella G., Zanasi A., Massimo Vanasia C.B. [Efficacy and safety of the use of levodropropizine in patients with chronic interstitial lung diseases]. Clin. Ter. 1991; 136 (4): 261–266 (in Italian).Bruschi C., Crotti P., Dacosto E. et al. Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment. Pulm. Pharmacol. Ther. 2003; 16 (4): 231–236. DOI: 10.1016/S1094-5539(03)00053-1.Bruschi C., Crotti P., Dacosto E. et al. Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment. Pulm. Pharmacol. Ther. 2003; 16 (4): 231–236. DOI: 10.1016/S1094-5539(03)00053-1.Mannini C., Lavorini F., Zanasi A. et al. A randomized clinical trial comparing the effects of antitussive agents on respiratory center output in patients with chronic cough. Chest. 2017; 151 (6): 1288–1294. DOI: 10.1016/j.chest.2017.02.001.Mannini C., Lavorini F., Zanasi A. et al. A randomized clinical trial comparing the effects of antitussive agents on respiratory center output in patients with chronic cough. Chest. 2017; 151 (6): 1288–1294. DOI: 10.1016/j.chest.2017.02.001.Nosalova G., Kardosova A, Franova S. Antitussive activity of a glucuronoxylan from Rudbeckia fulgida compared to the potency of two polysaccharide complexes from the same herb. Pharmazie. 2000; 55 (1): 65–68.Nosalova G., Kardosova A, Franova S. Antitussive activity of a glucuronoxylan from Rudbeckia fulgida compared to the potency of two polysaccharide complexes from the same herb. Pharmazie. 2000; 55 (1): 65–68.Catena E., Daff chio L. Effi acy and tolerability of levodropropizine in adult patients with non-productive cough. Comparison with dextromethorphan. Pulm. Pharmacol. Ther. 1997; 10 (2): 89–96. DOI: 10.1006/pupt.1997.0083.Catena E., Daff chio L. Effi acy and tolerability of levodropropizine in adult patients with non-productive cough. Comparison with dextromethorphan. Pulm. Pharmacol. Ther. 1997; 10 (2): 89–96. DOI: 10.1006/pupt.1997.0083.Luporini G., Barni S., Marchi E., Daffonchio L. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur. Respir. J. 1998; 12 (1): 97–101. DOI: 10.1183/09031936.98.12010097.Luporini G., Barni S., Marchi E., Daffonchio L. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur. Respir. J. 1998; 12 (1): 97–101. DOI: 10.1183/09031936.98.12010097.Затолочина К. Э., Зырянов С.К., Ушкалова Е.А. Леводропропизин: роль в лечении кашля. Педиатрия. Журнал им. Г.Н.Сперанского. 2020; 99 (5): 125–132. DOI: 10.24110/0031-403X-2020-99-5-125-132.Zatolochina K.E., Zyryanov S.K., Ushkalova E.A. [The role of levodropropizine in cough therapy]. Pediatriya. Zhurnal im. G.N.Sper­ anskogo. 2020; 99 (5): 125–132. DOI: 10.24110/0031-403X-2020-99-5-125-132 (in Russian).Zanasi A., Lanata L., Fontana G. et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip. Respir. Med. 2015; 10 (1): 19. DOI: 10.1186/s40248-015-0014-3.Zanasi A., Lanata L., Fontana G. et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip. Respir. Med. 2015; 10 (1): 19. DOI: 10.1186/s40248-015-0014-3.

The authors declare that there are no conflicts of interest present.